Merck finally has subcutaneous Keytruda results, and it's going to regulators
A decade after Keytruda hit the market, Merck has now said a subcutaneous version of the immunotherapy passed a
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
